Your session is about to expire
← Back to Search
Hallucinogen
Psilocybin for Depression in Alzheimer's
Verified Trial
Phase < 1
Recruiting
Led By Albert Garcia-Romeu, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Have you been diagnosed with Alzheimer’s Disease, early Alzheimer’s Disease, or Mild Cognitive Impairment? Mild Cognitive Impairment is a condition in which people experience memory problems beyond association with normal aging, but these symptoms are not as severe as those associated with Alzheimer’s Disease.
This study typically involves two in-person screening meetings in Baltimore, MD as well as 1-2 treatment meetings per week for 8 weeks. Most of the treatment meetings will be about 8-10 hours in length. Treatment will be followed by 3 follow-up meetings at 1, 3, and 6 months after treatment. If you meet the criteria for the study, could you make this time commitment?
Timeline
Screening 2 days
Treatment Varies
Follow Up 1 day
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if psilocybin, a substance from certain mushrooms, can safely improve depression and quality of life in people with early Alzheimer's or Mild Cognitive Impairment. It works by changing brain activity related to mood. Psilocybin has been studied for its potential to reduce depression and anxiety, particularly in patients with life-threatening conditions.
Who is the study for?
This trial is for people with mild cognitive impairment or early Alzheimer's who are currently depressed. Participants must be able to commit to several long treatment sessions in Baltimore, MD, and have a close friend or family member involved in the study. Exclusions include severe mental health conditions, certain cardiovascular issues, insulin-dependent diabetes, and those on specific medications.
What is being tested?
The trial is testing psilocybin's safety and effectiveness for treating depression in individuals with mild cognitive impairment or early Alzheimer's Disease. It aims to see if it can also improve their quality of life.
What are the potential side effects?
While not explicitly listed here, potential side effects of psilocybin may include nausea, headache, increased heart rate, blood pressure changes, and psychological effects such as anxiety or hallucinations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with Alzheimer's or Mild Cognitive Impairment.
Select...
I can attend long treatment sessions in Baltimore and follow-up meetings.
Select...
I am currently experiencing a depressive episode.
Select...
I have been diagnosed with Alzheimer's or Mild Cognitive Impairment.
Select...
I have someone close who can discuss changes in my mood and behavior for the study.
Timeline
Screening ~ 2 days2 visits
Treatment ~ Varies
Follow Up ~ 1 day3 visits
Screening ~ 2 days
Treatment ~ Varies
Follow Up ~1 day
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Cornell Scale for Depression in Dementia (CSDD) score
Secondary study objectives
Change in Quality of Life Alzheimer's Disease (QOL-AD) scale score
Side effects data
From 2021 Phase 2 trial • 95 Patients • NCT020612939%
Nausea
7%
Pain
7%
Viral upper resp. tract infection
7%
Back pain
7%
Bronchitis
4%
Diarrhea
4%
Influenza
4%
Headache
4%
Sinus headache
4%
Depressed mood
4%
Depression
4%
Insomnia
4%
Suicidal Ideation
4%
Lower resp. tract congestion
4%
Oropharyngeal pain
4%
Alcohol withdrawal syndrome
2%
Migraine
2%
Thrombocytosis
2%
Constipation
2%
Vomiting
2%
Oedema
2%
Peripheral swelling
2%
Pyrexia
2%
Dermatitis contact
2%
Bronchitis bacterial
2%
Eye infection
2%
Fungal infection
2%
Traumatic lung injury
2%
Hyponatremia
2%
Arthralgia
2%
Musculoskeletal pain
2%
Pain in extremity
2%
Malignant melanoma
2%
Dizziness
2%
Hypoesthesia
2%
Sedation
2%
Anger
2%
Anxiety
2%
Restlessness
2%
Cough
2%
Rhinorrhea
2%
Sinus congestion
2%
Sexual abuse
2%
Endodontic procedure
2%
Mallory-Weiss Syndrom
2%
Anemia
2%
Influenza like Illness
2%
Gingivitis
2%
Arthoscopic surgery
100%
80%
60%
40%
20%
0%
Study treatment Arm
Diphenhydramine
Psilocybin
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: PsilocybinExperimental Treatment1 Intervention
Participants will complete an 8-week course of study treatment including weekly psychological support and two moderate to high dose psilocybin administrations in weeks 4 and 6.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Psilocybin
2021
Completed Phase 2
~530
Find a Location
Who is running the clinical trial?
Johns Hopkins UniversityLead Sponsor
2,326 Previous Clinical Trials
14,874,709 Total Patients Enrolled
57 Trials studying Depression
29,522 Patients Enrolled for Depression
Albert Garcia-Romeu, MDPrincipal InvestigatorJohns Hopkins University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have been diagnosed with schizophrenia, a psychotic disorder (unless it was caused by drugs or a medical condition), or bipolar I disorder in the past or currently.I have tried various treatments for my current depressive episode, including psychotherapy, medications, and possibly ECT.I have been diagnosed with Alzheimer's or Mild Cognitive Impairment.I agree not to take medications like sildenafil within 72 hours before taking psilocybin.You have been diagnosed with depression, which can be mild or moderate based on a test called the Cornell Scale for Depression in Dementia. Or, you have been diagnosed with specific types of depression according to the DSM-5 diagnostic criteria.I am currently on antidepressants, antipsychotics, or MAO inhibitors.I have been diagnosed with depression or show signs of distress.I have no recent severe heart issues or uncontrolled high blood pressure.I have been diagnosed with early-stage Alzheimer's or mild cognitive impairment.I have a close family member with Schizophrenia, Psychotic Disorder, or Bipolar I.I have someone close who can discuss changes in my mood and behavior for the study.I have been diagnosed with early-stage Alzheimer's or mild cognitive impairment.You have a close friend or family member willing and able to serve the role of community observer / informant for data collection procedures.I am currently experiencing a depressive episode.I can attend long treatment sessions in Baltimore and follow-up meetings.I am currently experiencing a depressive episode.I have someone close who can discuss changes in my mood and behavior for the study.I have been diagnosed with Alzheimer's, early Alzheimer's, or Mild Cognitive Impairment.I can attend all required meetings in Baltimore for the study.I have been diagnosed with Alzheimer's or Mild Cognitive Impairment.I have a seizure disorder.I require insulin for my diabetes.
Research Study Groups:
This trial has the following groups:- Group 1: Psilocybin
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 2 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 10 null
- Follow Ups: You may be asked to continue sharing information regarding the trial for 1 Months after you stop receiving the treatment.
Depression Patient Testimony for trial: Trial Name: NCT04123314 — Phase < 1
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger